$ALGS

Aligos Therapeutics, Inc.

CIK:0001799448|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue from customers	$ 0	$ 965,000	$ 2,830,000	$ 1,276,000
Revenue from licensing agreements	27,778,000	0	27,778,000	0
Operating expenses:
Research and development	24,050,000	13,976,000	47,402,000	28,478,000
General and administrative	5,618,000	5,556,000	12,025,000	10,608,000
Total operating expenses	29,668,000	19,532,000	59,427,000	39,086,000
Loss from operations	(1,890,000)	(18,567,000)	(28,819,000)	(37,810,000)
Interest and other income, net	221,000	1,207,000	1,032,000	2,087,000
Change in fair value of 2023 Common Warrants	2,976,000	1,682,000	6,371,000	63,176,000
Income (loss) before income tax	1,307,000	(15,678,000)	(21,416,000)	27,453,000
Income tax provision	(2,811,000)	(185,000)	(3,128,000)	(228,000)
Net (loss) income	(1,504,000)	(15,863,000)	(24,544,000)	27,225,000
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(1,000)	(27,000)	(31,000)	(31,000)
Other comprehensive loss	(1,000)	(27,000)	(31,000)	(31,000)
Comprehensive (loss) income	$ (1,505,000)	$ (15,890,000)	$ (24,575,000)	$ 27,194,000
Net (loss) income per share, basic	$ (0.14)	$ (1.53)	$ (2.36)	$ 2.9
Net (loss) income per share, diluted	$ (0.14)	$ (1.53)	$ (2.36)	$ 2.9
Weighted average shares of common stock, basic	10,430,808	10,351,120	10,416,964	9,385,167
Weighted average shares of common stock, diluted	10,430,808	10,351,120	10,416,964	9,401,645

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net (loss) income, as reported	$ (24,544)	$ 27,225
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Accretion of discount on investments	(491)	(1,034)
Non cash lease expense	982	905
Change in fair value of 2023 Common Warrants	(6,371)	(63,176)
Depreciation expense	601	453
Stock-based compensation including ESPP	2,678	2,119
Changes in operating assets and liabilities:
Accounts payable	2,449	1,328
Accrued liabilities	5,170	(3,352)
Operating lease liabilities	(1,665)	(1,499)
Other liabilities	(47)	0
Deferred revenue	0	428
Accounts receivable	(27,778)	0
Other assets	938	190
Net cash and cash equivalents used in operating activities	(48,078)	(36,413)
Cash flows from investing activities:
Maturities of short-term investments	60,000	20,000
Purchase of short-term investments	0	(103,336)
Purchases of property and equipment	(70)	(152)
Net cash and cash equivalents provided by (used in) investing activities	59,930	(83,488)
Cash flows from financing activities:
Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with 2025 PIPE Offering, net of costs	0	101,386
Payments on finance lease	(78)	(1)
Proceeds from the ESPP purchase	236	180
Net cash and cash equivalents provided by financing activities	158	101,565
Net increase (decrease) in cash, cash equivalents, and restricted cash	12,010	(18,336)
Cash, cash equivalents, and restricted cash, beginning of period	18,413	37,107
Cash, cash equivalents, and restricted cash, end of period	30,423	18,771
Supplemental disclosures of noncash financing and investing activities:
PIPE issuance costs unpaid at period end	$ 0	$ (41)

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 30,381,000	$ 18,303,000
Restricted cash	42,000	110,000
Short-term investments	0	59,541,000
Accounts receivable	27,778,000
Other current assets	3,926,000	4,908,000
Total current assets	62,127,000	82,862,000
Operating lease right-of-use assets	2,107,000	3,089,000
Property and equipment, net	1,334,000	1,867,000
Other assets	759,000	715,000
Total assets	66,327,000	88,533,000
Current liabilities:
Accounts payable	6,431,000	3,982,000
Accrued liabilities	18,696,000	13,526,000
Operating lease liabilities, current	3,152,000	3,580,000
Finance lease liabilities, current	64,000	145,000
Total current liabilities	28,343,000	21,233,000
Operating lease liabilities, net of current portion	288,000	1,525,000
2023 Common Warrants liability	5,812,000	12,183,000
Long term liability	0	47,000
Total liabilities	34,443,000	34,988,000
Commitments and contingencies (Note 10)
Stockholders' equity
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.	0	0
Common stock, $0.0001 par value; 115,800,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,236,828 and 6,178,230 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.	9,000	9,000
Additional paid-in capital	698,183,000	695,269,000
Accumulated deficit	(666,745,000)	(642,201,000)
Accumulated other comprehensive income	437,000	468,000
Total stockholders' equity	31,884,000	53,545,000
Total liabilities and stockholders' equity	$ 66,327,000	$ 88,533,000